IACS-13909 |
Katalog-Nr.GC62345 |
IACS-13909 ist ein selektiver, potenter und oral wirksamer allosterischer SHP2-Inhibitor mit einem IC50 von 15,7 nM und einem Kd von 32 nM. IACS-13909 ist selektiver fÜr SHP2 als andere Phosphatasen (einschließlich SHP1). IACS-13909 hat AntitumoraktivitÄten und unterdrÜckt die SignalÜbertragung des MAPK-Wegs bei Rezeptortyrosinkinasen (RTK)-abhÄngigen Krebsarten.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2160546-07-4
Sample solution is provided at 25 µL, 10mM.
IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers[1].
IACS-13909 (10 nM-10 μM; 14 days) treatment potently suppresses the proliferation of wild-type SHP2 and KYSE-520 cells[1].IACS-13909 (1-5 μM; 2 hours) treatment potently suppresses pERK and pMEK levels in wild-type SHP2 and KYSE-520 cells[1].IACS-13909 potently suppresses the proliferation of both the parental cells and NCI-H1975 CS cells in a dose-dependent manner, with similar potency (GI50 ~1 μM). IACS-13909 (0.041-3.3 μM) suppresses pERK in NCI-H1975 CS cells in a dose-dependent manner[1].
IACS-13909 (70 mg/kg; oral administration; daily; for 21 days) treatment potently suppresses tumor growth in mice, with 100% tumor growth inhibition (TGI) observed following 21 days of dosing[1].
[1]. Yuting Sun, et al. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 2020 Nov 1;80(21):4840-4853.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *